GeoVax Labs, Inc. New - GOVX STOCK NEWS

GeoVax Labs (Nasdaq: GOVX) will be represented by Dr. Mark J. Newman at the World Vaccine & Immunotherapy Congress in San Diego from November 28 to December 1, 2022. He will focus on advancing pan-coronavirus vaccines aimed at combating evolving variants. Dr. Newman will share insights on GeoVax's COVID-19 vaccine, GEO-CM04S1, currently in Phase 2 trials as a primary vaccine for immunocompromised individuals and as a booster for healthy patients. The presentation is scheduled for November 29 at 2:50 p.m. PT.

GeoVax Labs, Inc. (GOVX) announced its third-quarter financial results for 2022, reporting a net loss of $3.97 million ($0.17 per share), compared to a loss of $1.95 million ($0.31 per share) in the same quarter of 2021. The company is advancing its COVID-19 vaccine GEO-CM04S1 in Phase 2 trials and has secured rights to NIH-MVA for potential use against Monkeypox and Smallpox. With cash reserves of $34.7 million, GeoVax plans to accelerate patient enrollment and expand its clinical programs, enhancing its position in the biopharmaceutical landscape.

GeoVax Labs, Inc. (Nasdaq: GOVX) announced it will release its third quarter 2022 financial results on November 9, 2022, after market close. The company will follow with a live conference call and webcast at 4:30 PM EST for a business update and financial discussion, including a Q&A session. GeoVax is focused on developing immunotherapies and vaccines for cancer and infections, with ongoing Phase 1/2 trials for its oncology program, Gedeptin®, and COVID-19 vaccine candidate GEO-CM04S1. A replay of the call will be available for a limited time.

GeoVax Labs (Nasdaq: GOVX) has announced a presentation at the Vaccines Summit-2022, focusing on their COVID-19 vaccine, GEO-CM04S1, which is in Phase 2 clinical trials. Senior Scientist Dr. Sreenivasa Oruganti will address challenges from emerging COVID-19 variants and vaccine efficacy. The presentation is scheduled for October 12, 2022. GeoVax is also developing a second pan-coronavirus vaccine, GEO-CM02, aimed at providing universal coverage without strict refrigeration needs. Both vaccines target immunocompromised patients and healthy individuals.

GeoVax Labs, Inc. (Nasdaq: GOVX) announced that its Chairman & CEO, David Dodd, will present at two major events: the Midcap Rodeo: Windy City Roundup 2022 in Chicago from October 11-13, 2022, and the LD Micro Main Event XV in Los Angeles from October 25-27, 2022. Dodd's presentation in Chicago is scheduled for October 12 at 10:30 AM CDT, while the Los Angeles presentation will take place on October 26 at 9:30 AM PDT. GeoVax is focused on developing vaccines and immunotherapies for infectious diseases and cancer.

GeoVax Labs, a biotechnology company focused on vaccine development, will present updates on its clinical trials at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022. The CEO, David Dodd, will discuss the Phase 2 trials for the COVID-19 vaccine GEO-CM04S1 and the Phase 1/2 trial for Gedeptin®, aimed at treating advanced head and neck cancer. GeoVax is also developing vaccines for other viral diseases and has over 70 patents. A webcast of the presentation will be available online.

GeoVax Labs, Inc. (Nasdaq: GOVX) has appointed Nicole Lemerond, CFA, a seasoned financial executive with over 25 years in healthcare finance, to its Board of Directors. Lemerond's extensive background includes experience in investment management and healthcare transactions, making her a valuable asset as GeoVax advances its product development portfolio. The company is currently engaged in multiple clinical trials, including a COVID-19 vaccine and treatments for cancer. This leadership change may enhance capital-raising efforts and strategic initiatives.

GeoVax Labs (GOVX) reported its financial results for Q2 2022, revealing a net loss of $2.2 million ($0.21 per share), compared to a loss of $1.3 million ($0.18 per share) in Q2 2021. The company is advancing its Phase 2 clinical trials for its COVID-19 vaccine, GEO-CM04S1, targeting immunocompromised cancer patients. Cash balances increased to $30.9 million following fundraises of $18.5 million in May and $9.2 million in January. With these resources, GeoVax is focused on accelerating clinical trials and enhancing its pipeline in vaccines and immunotherapies.

GeoVax Labs (GOVX) announced the publication of a peer-reviewed animal efficacy study for its MVA-VLP-SUDV vaccine against Sudan ebolavirus, published in Nature Partner Journals Vaccines. The study demonstrated that guinea pigs vaccinated with one or two doses generated strong immune responses, achieving 100% protection against SUDV post-exposure. The vaccine integrates live attenuated vector advantages with virus-like particle technology, facilitating emergency responses. The company aims to initiate nonhuman primate trials soon, further validating its vaccine platform.